Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Andrew Solomon

Rheumatology Bothell, WA Medical Doctor

NPI 1588607808 CMS profile 117190

1909 214Th St Se Ste 211, Bothell, WA 98021

Open in the dashboard

General payments

$47,498

290 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Andrew Solomon of Bothell, WA is reported in the CMS Open Payments database as having received $47,498 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $239 4
2021 General $4,871 35
2020 General $5,927 53
2019 General $36,460 198

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Solomon
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Andrew Solomon were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Andrew Solomon Rheumatology median Middle half National median
2019 $36,460 $744 $153–$2,687 $163
2020 $5,927 $462 $98–$2,027 $114
2021 $4,871 $531 $101–$2,153 $132
2022 $239 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Celgene Corporation $32,092 51 payments
  2. Amgen Inc. $10,053 39 payments
  3. Janssen Biotech, Inc. $2,519 47 payments
  4. Horizon Therapeutics plc $643 23 payments
  5. Novartis Pharmaceuticals Corporation $284 21 payments
  6. Lilly USA, LLC $216 9 payments
  7. AbbVie, Inc. $216 12 payments
  8. GlaxoSmithKline, LLC. $213 13 payments
  9. E.R. Squibb & Sons, L.L.C. $202 16 payments
  10. UCB, Inc. $185 5 payments
  11. Other $873 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,391 9 payments
  2. Consulting Fee $8,588 4 payments
  3. Travel and Lodging $7,155 22 payments
  4. Food and Beverage $5,363 255 payments
Products named General payments · program years 2019–2022
  1. Otezla Dermatology $32,027 40 payments
  2. Otezla Inflammation $9,524 15 payments
  3. SIMPONI ARIA $2,502 45 payments
  4. KRYSTEXXA $557 17 payments
  5. STELARA $307 25 payments
  6. Prolia $305 15 payments
  7. TREMFYA $286 17 payments
  8. COSENTYX $243 19 payments
  9. Enbrel $233 10 payments
  10. BENLYSTA $213 13 payments
  11. Other $2,378 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record